A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults (C-013-404)

A Phase I Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of BCG and AERAS-404 Administered as a Prime-Boost Regimen to HIV-Negative, TB-Negative, BCG-Naive Adults

70 subjects received BCG intradermally at Study Day -42, then at Study Day 0 were randomized to receive AERAS-404 50 mcg H4/500 nmol IC31 intramuscularly as a 3-dose (N=30) or 2-dose (N=30) regimen, or placebo (N=10). Subjects were vaccinated on Study Days 0, 56, and 231, and followed through Study Day 259.

Study Overview

• Status: Completed
• Conditions: Tuberculosis
• Intervention / Treatment: Biological: BCG SSI; Biological: Placebo; Biological: AERAS-404

Detailed Description

A total of 70 subjects who had received BCG at Study Day -42 were randomized on Study Day 0 to receive 3 doses of placebo (N=10); 1 dose of placebo followed by 2 doses of AERAS-404 (N=30; AERAS-404 2 dose regimen); or 3 doses of AERAS-404 (N=30; AERAS-404 3 dose regimen). A total of 69 (98.6%) subjects completed the study; the remaining subject, in the AERAS-404 2 dose regimen, withdrew consent. All 70 subjects received the first and second vaccinations with placebo or AERAS-404 on Study Days 0 and 56, and 67 (95.7%) subjects received the third vaccination on Study Day 231. Three subjects did not receive the Study Day 231 vaccination (2 in the AERAS-404 2 dose regimen, 1 due to withdrawal of consent and 1 due to pregnancy [the subject delivered a healthy boy without complications and was followed to study completion]; and 1 in the AERAS-404 3 dose regimen, due to inability to discontinue daily isotretinoin started after the second vaccination [the subject was followed to study completion]).

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Phase 1

Contacts and Locations

Study Locations

• Switzerland
  • Vaud
    • Lausanne, Vaud, Switzerland
      • Centre Hosptialier Universitaire Vaudois (CHUV)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Had completed the written informed consent process.
2. Was male or female.
3. Was age ≥ 18 years and ≤ 50 years.
4. Agreed to stay in contact with the study site for the duration of the study, provide updated contact information as necessary, and had no current plans to move from the study area for the duration of the study.
5. Agreed to avoid elective surgery for the duration of the study.
6. Had completed simultaneous enrollment in Aeras Vaccine Development Registry protocol.
7. For female subjects: agreed to avoid pregnancy from 28 days prior to Study Day 0 through the duration of the study.
8. Had general good health, confirmed by medical history and physical examination.
9. Had body mass index (BMI) between 18 and 33 (weight/height2) by nomogram.

Exclusion Criteria:

1. Oral temperature ≥37.5°C.
2. Abnormal CBC laboratory values (per local laboratory parameters) from blood collected at screening (>5% above ULN or >5% below LLN).
3. Abnormally elevated laboratory values (per local laboratory parameters) from blood collected at screening for ALT, AST, GGT, total bilirubin, alkaline phosphatase (ALP), blood urea nitrogen (BUN), creatinine, prothrombin time (PT), or partial thromboplastin time (PTT) (>10% above ULN).
4. Abnormal urinalysis that, in the opinion of the investigator, was clinically significant.
5. Positive screening urine test for illicit drugs (opiates, cocaine, amphetamines).
6. History or evidence of active or latent tuberculosis infection, including a positive QuantiFERON-TB test, a history of a positive TST, or abnormal chest X-ray findings that in the opinion of the investigator were evidence of tuberculosis.
7. Residence longer than 6 months in a high-burden country (per WHO 2010 TB Report).
8. Shared a residence within 1 year prior to Study Day -42 with an individual on anti-tuberculosis treatment or with culture- or smear-positive pulmonary tuberculosis.
9. Previous treatment for active or latent tuberculosis infection.
10. History or evidence of autoimmune disease.
11. History or evidence of any past, present, or future possible immunodeficiency state, including laboratory evidence of HIV 1 infection.
12. History or evidence of chronic hepatitis, including hepatitis B core antibody or hepatitis C antibody.
13. Received a TST within 90 days prior to Study Day -42.
14. Received a systemic antibiotic with 14 days prior to Study Day -42.
15. Received BCG vaccination or BCG immunotherapy prior to Study Day -42.
16. Received investigational Mtb vaccine.
17. Participation in any other investigational study during the study period.
18. Current household contact with an individual with known significant immunosuppression.
19. Occupational exposure that would have put an immunocompromised individual at risk, unless measures could be taken to reduce this risk to an acceptable level (e.g., plaster on the injection site).
20. Received immunoglobulin or blood products within 90 days prior to Study Day -42.
21. Received any investigational drug therapy or investigational vaccine within 180 days prior to Study Day -42.
22. Received any licensed vaccine within 45 days prior to Study Day -42 (note: the use of licensed vaccines medically indicated during the study was permitted at any time).
23. Received immunosuppressive medications other than inhaled or topical immunosuppressants within 45 days prior to Study Day -42.
24. Inability to discontinue daily medications other than the following during the study: oral contraceptives, vitamins, nonprescription nutritional supplements, aspirin, antihistamines, antihypertensives, antidepressants.
25. All female subjects: currently pregnant or lactating/nursing; positive screening urine pregnancy test; or positive urine pregnancy test on the day of any study vaccination.
26. History or evidence of allergic disease or reaction that, in the opinion of the investigator, may have compromised the safety of the subject.
27. History or evidence of dermatologic disease that, in the opinion of the investigator, may have interfered with the assessment of injection site reactions.
28. History or evidence of any other acute or chronic disease that, in the opinion of the investigator, may have interfered with the evaluation of the safety or immunogenicity of the vaccine or compromise the safety of the subject.
29. Medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, would make it unlikely that the subject would comply with the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: BCG SSI prime with Placebo; All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42. Placebo containing 0,8 mL sterile buffer consisting of 10 mmol Tris and 169 mmol NaCl aqueous solution was administered on Study Days 0, 56, and 231.	Biological: BCG SSI; The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.; Other Names: BCG Vaccine SSI Danish; bacillus Calmette-Guérin; Biological: Placebo; This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.; Other Names: Sterile buffered saline
Experimental: BCG SSI prime with Placebo and AERAS-404; All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42. Placebo on Study Day 0 followed by AERAS-404 50/500 on Study Days 56 and 231. AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows: H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.; IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl.	Biological: BCG SSI; The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.; Other Names: BCG Vaccine SSI Danish; bacillus Calmette-Guérin; Biological: Placebo; This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.; Other Names: Sterile buffered saline; Biological: AERAS-404; AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.; Other Names: H4:IC31
Experimental: BCG SSI prime with AERAS-404; All subjects received BCG Vaccine SSI, 2-8 x 10^5 CFU (BCG) on Study Day -42. AERAS-404 50/500 on Study Days 0, 56, and 231. AERAS-404 50/500 was a fixed dose combination of H4 50 mcg and IC31 500 nmol (KLK equivalent). H4 and IC31 adjuvant were supplied as separate single-dose vials containing frozen product as follows: H4 antigen: 500 mcg/mL (100 mcg/0.2 mL), in 10 mmol/L Tris-HCl, pH 8.3.; IC31 adjuvant: 1250 nmol/mL (1000 nmol/0.8 mL) KLK equivalent, in 10 mmol/L Tris-HCl and 169 mmol/L NaCl.	Biological: BCG SSI; The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.; Other Names: BCG Vaccine SSI Danish; bacillus Calmette-Guérin; Biological: AERAS-404; AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.; Other Names: H4:IC31

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of unsolicited, solicited, and serious adverse events (SAEs).	Includes injection site AEs and systemic AEs.	259 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Immunogenicity of BCG and a 2- or 3-dose regimen of AERAS-404 measured by intracellular staining assay (ICS).	ICS permits the detection of antigen-specific cytokine responses with a distinction between CD4+ and CD8+ T cells.	259 Days

Collaborators and Investigators

• Sponsor: Aeras
• Collaborators: Sanofi Pasteur, a Sanofi Company
• Investigators: Principal Investigator: Giuseppe Pantaleo, MD, Centre Hosptialier Universitaire Vaudois (CHUV)

Study record dates

Study Major Dates

• Study Start: January 1, 2011
• Primary Completion (Actual): May 1, 2012
• Study Completion (Actual): November 1, 2013

Study Registration Dates

• First Submitted: April 15, 2015
• First Submitted That Met QC Criteria: April 16, 2015
• First Posted (Estimate): April 17, 2015

Study Record Updates

• Last Update Posted (Estimate): January 24, 2017
• Last Update Submitted That Met QC Criteria: January 23, 2017
• Last Verified: January 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Actinomycetales Infections; Mycobacterium Infections; Tuberculosis; Physiological Effects of Drugs; Immunologic Factors; Adjuvants, Immunologic; BCG Vaccine
• Other Study ID Numbers: C-013-404

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED